Adaptive Biotechnologies (NASDAQ:ADPT) Upgraded by Wall Street Zen to “Buy” Rating

Adaptive Biotechnologies (NASDAQ:ADPT) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Sunday.

ADPT has been the subject of a number of other research reports. Guggenheim lifted their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Piper Sandler set a $21.00 price target on shares of Adaptive Biotechnologies in a research report on Friday. Morgan Stanley began coverage on shares of Adaptive Biotechnologies in a research note on Monday, December 1st. They set an “equal weight” rating and a $21.00 price objective for the company. JPMorgan Chase & Co. increased their price objective on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Friday. Finally, TD Cowen reissued a “buy” rating on shares of Adaptive Biotechnologies in a report on Friday. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.56.

Adaptive Biotechnologies Price Performance

Shares of ADPT opened at $15.77 on Friday. The company’s fifty day moving average price is $17.03 and its 200-day moving average price is $15.23. Adaptive Biotechnologies has a 1-year low of $6.26 and a 1-year high of $20.76. The firm has a market capitalization of $2.41 billion, a PE ratio of -39.42 and a beta of 2.18.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.10. The company had revenue of $71.68 million during the quarter, compared to analysts’ expectations of $59.38 million. Adaptive Biotechnologies had a negative return on equity of 48.73% and a negative net margin of 21.48%.The firm’s revenue was up 51.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.23) EPS. As a group, research analysts anticipate that Adaptive Biotechnologies will post -0.92 EPS for the current fiscal year.

Insider Activity

In related news, CFO Kyle Piskel sold 162,820 shares of the business’s stock in a transaction on Friday, November 28th. The shares were sold at an average price of $19.50, for a total value of $3,174,990.00. Following the completion of the transaction, the chief financial officer directly owned 216,637 shares in the company, valued at $4,224,421.50. The trade was a 42.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Francis Lo sold 113,890 shares of the stock in a transaction on Monday, December 15th. The stock was sold at an average price of $15.57, for a total transaction of $1,773,267.30. Following the sale, the insider directly owned 315,978 shares in the company, valued at $4,919,777.46. This trade represents a 26.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 1,612,461 shares of company stock valued at $27,754,413 in the last quarter. Company insiders own 6.40% of the company’s stock.

Institutional Investors Weigh In On Adaptive Biotechnologies

A number of institutional investors have recently modified their holdings of the business. Ameriprise Financial Inc. increased its stake in shares of Adaptive Biotechnologies by 84.3% in the 3rd quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock valued at $89,337,000 after purchasing an additional 2,731,648 shares in the last quarter. Geode Capital Management LLC grew its holdings in Adaptive Biotechnologies by 15.6% in the second quarter. Geode Capital Management LLC now owns 3,215,171 shares of the company’s stock valued at $37,461,000 after purchasing an additional 434,347 shares during the period. Aristotle Atlantic Partners LLC grew its holdings in Adaptive Biotechnologies by 8.6% in the third quarter. Aristotle Atlantic Partners LLC now owns 3,126,719 shares of the company’s stock valued at $46,776,000 after purchasing an additional 247,402 shares during the period. Jennison Associates LLC increased its position in shares of Adaptive Biotechnologies by 103.9% in the fourth quarter. Jennison Associates LLC now owns 2,674,668 shares of the company’s stock valued at $43,437,000 after buying an additional 1,363,181 shares in the last quarter. Finally, Fred Alger Management LLC raised its stake in shares of Adaptive Biotechnologies by 6.7% during the 3rd quarter. Fred Alger Management LLC now owns 2,514,234 shares of the company’s stock worth $37,613,000 after buying an additional 158,807 shares during the period. 99.17% of the stock is currently owned by institutional investors and hedge funds.

Adaptive Biotechnologies News Roundup

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Q4 results beat expectations — ADPT reported a $0.09 loss per share vs. a $0.19 consensus loss and revenue of $71.7M (up 51% YoY), which investors typically view as positive for growth outlook. Read More.
• Positive Sentiment: Analyst upgrade/target increase — JPMorgan raised its price target to $21 and maintained an overweight stance, implying meaningful upside versus recent levels and likely supporting buying interest. Read More.
• Neutral Sentiment: Multiple analyst write-ups and coverage: Zacks and other outlets published detail and comparisons to estimates; consensus remains a “Moderate Buy” with an average price target near the mid‑teens to low‑$20s — useful context but not a single catalyst. Read More.
• Neutral Sentiment: Full earnings materials and transcript are available for deeper review (management commentary and slide deck will guide whether revenue quality and guidance justify the rally). Read More.
• Negative Sentiment: Significant insider selling disclosed this week — CEO Chad M. Robins and other insiders sold large blocks (CEO ~125k shares; other insider sales also reported). Large insider sales can pressure sentiment even when results are strong. Read More.
• Negative Sentiment: Company remains unprofitable with negative margins and a negative ROE; analysts still expect a full-year loss (consensus EPS negative), which leaves valuation and timing of profitability as ongoing investor concerns. Read More.
• Neutral Sentiment: Reported short-interest data in this batch is effectively zero/unchanged and shows no immediate short‑squeeze dynamics; days‑to‑cover computed as 0.0, so short interest is not a current market driver. (Item flagged in recent data feeds.)

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.